Brain Disorders: NT 0150 Study

We are investigating a new compound, NT 0150, for its safety and how it is absorbed and eliminated in the body. This research may help in developing treatments for Alzheimer's and Parkinson's disease.

6-12 monthsSafety phase (I)Internal MedicineNeurology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Pharmaceutical Research Associates Group B.V.
Program Management
Groningen, Netherlands
Sponsor: Nodthera Limited
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.